Moreover, some new targeted drugs such as infliximab (a monoclonal antibody against tumor necrosis factor-α /TNF-α), ustekinumab (a monoclonal antibody against the p40 subunit of interleukin 12/23), and adalimumab (a fully human neutralizing anti-TNFα monoclonal antibody) are also used to treat IBD patients (Fiske et al., 2022; Lerang et al., 2022; Song et al., 2022; Wasserbauer et al., 2022; Yao et al., 2022). The gene discussed is TNF; the disease is inflammatory bowel disease.